Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

@article{Chew2015CiliaryNF,
  title={Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.},
  author={Emily Y. Chew and Traci E Clemons and Tunde Peto and Ferenc B Sallo and Avner Ingerman and Weng Tao and Lawrence J. Singerman and Steven D Schwartz and Neal S Peachey and Alan C. Bird},
  journal={American journal of ophthalmology},
  year={2015},
  volume={159 4},
  pages={
          659-666.e1
        }
}
PURPOSE To evaluate the safety and tolerability of intraocular delivery of ciliary neurotrophic factor (CNTF) using an encapsulated cell implant for the treatment of macular telangiectasia type 2. DESIGN An open-label safety trial conducted in 2 centers enrolling 7 participants with macular telangiectasia type 2. METHODS The participant's more severely affected eye (worse baseline visual acuity) received the high-dose implant of CNTF. Patients were followed for a period of 36 months. The… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Management of Idiopathic Macular Telangiectasia Type 2

  • Ophthalmology and therapy
  • 2019
VIEW 8 EXCERPTS
HIGHLY INFLUENCED

Vitreoretinal Disorders

  • Current Practices in Ophthalmology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…